Primary pulmonary diffuse large B-cell lymphoma
✍ Scribed by Tomasz Wróbel; Justyna Dzietczenia; Monika Prochorec–Sobieszek; Grzegorz Mazur; Piotr Piwkowski
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 634 KB
- Volume
- 87
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Prognosis of DLCL patients is variable and associated with well-de®ned risk factors. In the past decade several pretreatment variables have been incorporated into prognostic models to predict the death risk of individual patients. The International Prognostic Index (IPI), developed in an internation
## Abstract Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an ‘aggressive B‐cell non‐Hodgkin's lymphoma’, characterized by a high degree of proliferation of the malignant cells and deregulation of the c‐MYC gene. The main diagnostic chal
## Abstract Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an “aggressive B‐cell non‐Hodgkin's lymphoma”, characterized by a high degree of proliferation of the malignant cells and deregulation of the c‐__MYC__ gene. The main diagnostic
B-lineage diffuse large cell lymphoma (B-DLCL) arising de novo is chatacterized by a marked degree of clinical heterogeneity. To determine whether or not the clinical heterogeneity of de novo B-DLCL is reflected by heterogeneity in the molecular features of these tumors, we investigated the pattern